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0022-2836/$ - see front matter © 2007 EWe have studied the effects of the extracellular molecular chaperone,
clusterin, on the in vitro aggregation of mutational variants of human
lysozyme, including one associated with familial amyloid disease. The
aggregation of the amyloidogenic variant I56T is inhibited significantly at
clusterin to lysozyme ratios as low as 1:80 (i.e. one clusterin molecule per 80
lysozyme molecules). Experiments indicate that under the conditions where
inhibition of aggregation occurs, clusterin does not bind detectably to the
native or fibrillar states of lysozyme, or to the monomeric transient
intermediate known to be a key species in the aggregation reaction. Rather,
it seems to interact with oligomeric species that are present at low con-
centrations during the lag (nucleation) phase of the aggregation reaction.
This behavior suggests that clusterin, and perhaps other extracellular
chaperones, could have a key role in curtailing the potentially pathogenic
effects of the misfolding and aggregation of proteins that, like lysozyme, are
secreted into the extracellular environment.© 2007 Elsevier Ltd. All rights reserved.Keywords: human lysozyme; systemic amyloidosis; clusterin; chaperones;
fibril formation*Corresponding authorIntroduction
Protein misfolding that results in the formation of
aggregates is associated with a range of human
diseases, including both organ-specific conditions,
such as Alzheimer's disease and type II diabetes, and
systemic conditions, such as the non-neuropathic
amyloidoses associated with the proteins transthyr-
etin and lysozyme.1 Since 1993, six naturally
occurring lysozyme variants associated with amy-
loid disease (I56T, F57I, F57I/T70N, W64R, D67H
and T70N/W112R),2–5 and one non-amyloidogenic
variant (T70N),6 have been discovered. In-depth
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related T70N variant, has been performed using a
variety of biophysical techniques.7–14 Deposits of
I56T and D67H formed in vitro possess the key
characteristics of amyloid fibrils; these include their
fibrillar morphology in TEM images, their displays
of birefringence upon binding the dye Congo red
and a typical cross-β X-ray diffraction pattern.10–12
The kinetics of in vitro fibril formation by both I56T
and D67H are sigmoidal, showing a lag phase
followed by an exponential growth phase typical of
amyloidogenic systems.10–12 Furthermore, fibril for-
mation by I56T, D67H and wild-type lysozymes can
be accelerated by seeding with pre-formed fibrils,12
indicating that lysozyme fibril formation proceeds
through a nucleation-dependent mechanism.15
The native state of lysozyme consists of two
structural regions, one predominantly helical (the
α-domain) and the other containing significant
β-sheet structure (the β-domain). The amyloido-
genic nature of the disease-associated lysozyme
variants has been found to result from a reductiond.
158 Clusterin Inhibits Lysozyme Amyloid Formationin native state stability and cooperativity, which
allows the population of a transient and aggre-
gation-prone partially unfolded intermediate
under physiologically relevant conditions. In
this intermediate, the β-domain and an adjacent
helix (C-helix) of the α-domain are unfolded
simultaneously, whereas the regions forming the
remainder of the protein fold maintain their
native-like structure.9,11
The ability of proteins to misfold, and even to
form organized aggregated species such as amyloid
fibrils, is inherent in their nature and can occur in
vivo either during the initial folding process
following biosynthesis, or later as a result of the
intrinsic fluctuations in their conformations.16 The
systemic amyloidoses are of particular interest, as
pathogenicity appears to be determined primarily
as a consequence of the disruption of vital organs
by large, often massive, accumulations of aggre-
gated proteins.17 Biological systems have therefore
evolved a variety of mechanisms to avoid such
aggregation under normal conditions. As well as
the evolutionary design of the sequence of amino
acids, these protective mechanisms include quality
control and degradation processes, and the pre-
sence of a wide range of molecular chaperones.18
The latter are of considerable importance; however,
the vast majority of known chaperones are found
inside the cell, whilst the bulk of proteinaceous
aggregates accumulate in extracellular space.19,20 It
is therefore of particular importance, in the context
of amyloid disease, that three extracellular chaper-
ones have been recently discovered.19
The best characterized of these molecular chaper-
ones is clusterin, a ∼61 kDa glycoprotein that is
translated as a 449 amino acid residue single
polypeptide chain, the first 22 of which represent a
secretory signal that is proteolytically cleaved after
biosynthesis.21,22 Post-translational modification
results in an N-linked glycosylated protein that is
also cleaved proteolytically into an α and β-peptide
that are concomitantly linked by five disulfide bonds
to form a heterodimer.22 Clusterin is distributed
widely throughout the body, with average concen-
trations in human plasma of 100(±50) μg/ml,
although levels in human seminal fluid are about
ten times higher.23,24 The precise physiological role
of clusterin is unknown, although a large diversity of
functions has been suggested.25 In particular, it has
been shown that the chaperone behavior of clusterin
can be observed in vitro and appears similar to that
described for the small heat shock proteins.26,27
Clusterin has been reported to inhibit in vitro fibril
formation by a number of proteins and peptides
linked to aggregation diseases including the Aβ
peptide, apo C-II, and the prion neuropeptide 106–
126.19,40
A wide range of biophysical and biochemical
techniques has been used over some years to
explore, in vitro, the molecular mechanism by
which disease-associated variants of human lyso-
zyme form amyloid fibrils, and to relate these
findings to the likely origin of the familial systemicamyloidosis with which extracellular deposits of
these species are associated.9,10 In the present
study we have utilized our extensive knowledge
of this system to examine the effects of clusterin on
the aggregation reaction of a globular protein, and
hence to explore the possible significance in the
prevention of widespread deposition of extracel-
lular proteins in living systems.Results
The process of fibril formation in the present study
has been explored by investigating the amyloido-
genic lysozyme variant, I56T, as well as a non-
natural variant of human lysozyme, I59T, which
possesses the same mutation in a similar region of
the structure, but which has greater stability and
cooperativity than the natural amyloidogenic var-
iants (our unpublished results). For both proteins,
amyloid fibrils were observed to form at pH 5.0 and
they appeared similar to those reported previously
(Figures 1 and 2). In order for fibrils to form on
suitable time-scales for these experiments, tempera-
tures of 48 °C (for I56T) and 60 °C (for I59T) were
chosen. Using a light-scattering assay, we initially
monitored the aggregation of each protein in the
presence and in the absence of substoichiometric
amounts of clusterin over time-spans of 90 h for I56T
(Figure 1(a)) and 10 h for I59T (Figure 2(a)). In the
absence of clusterin, fibrils formed readily in both
cases, with half-times for the aggregation process of
26(±6) h for I56T and 2.8(±0.6) h for I59T. In the
presence of a 1:40 clusterin-to-lysozyme molar ratio,
the changes in light-scattering were essentially
completely absent for both variants on these time-
scales. Complete inhibition over the time-courses
studied here was also found with clusterin-to-
lysozyme molar ratios of 1:4, 1:8 and 1:80. The
observed inhibitory effect was specific to the
presence of clusterin and was not seen upon
addition of similar ratios of conalbumin or bovine
serum albumin (BSA) to lysozyme undergoing
aggregation (data not shown). At the ends of the
incubation times, each sample was analyzed by
transmission electron microscopy (Figures 1(b) and
2(b)) and the fluorescence of the amyloid-binding
dye, thioflavin Twasmeasured (Figures 1(c) and 2(c)).
In addition, the samples were passed through
0.22 μm pore size filters followed by analysis of
the flow-through by SDS-PAGE to determine the
quantities of soluble protein present in the solutions
(Figures 1(d) and 2(d)). These procedures revealed
that the samples of I56T and I59T in the absence of
clusterin had converted almost completely into
amyloid fibrils. However, in each of the samples
containing clusterin, no such fibrillar aggregates
were observed and a large proportion of the
lysozyme molecules (>95%) were still present in
solution. Some non-fibrillar aggregates could be
observed in the lysozyme samples containing
clusterin, but similar species were visible also in
clusterin samples in the absence of the lysozyme
Figure 1. Inhibition of I56T lysozyme fibril formation by clusterin. (a) Light-scattering results from I56T lysozyme
aggregation in the absence (black) and presence of clusterin (red) at a 1:40 clusterin-to-lysozyme molar ratio. The light-
scattering intensity for clusterin alone is shown in blue. Samples were incubated with stirring at 48 °C and light-scattering
was monitored at 500 nm. (b) TEM analysis of samples taken at the end of the growth phase observed in the light-
scattering assay. The scale bar represents 1 μm. (c) Thioflavin-T fluorescence measured at the end of the growth phase
observed in the light-scattering assay for buffer only (green), I56T lysozyme alone (black) and I56T lysozyme with
clusterin (red). (d) SDS-PAGE analysis of samples at the end of the growth phase observed in the light-scattering assay
after being passed through 0.22 μm pore size filters. No soluble protein remained in the I56T sample in the absence of
clusterin (lane 1); in contrast, the majority of lysozyme remained in the soluble form in the sample containing clusterin
(lane 2). Molecular mass markers are shown in lane M, and an equal volume of a soluble I56T lysozyme solution (7 μM) is
shown in lane S.
159Clusterin Inhibits Lysozyme Amyloid Formationvariants, albeit in smaller quantities. These species
may, therefore, be the result of slow aggregation of
clusterin as well as of lysozyme itself under our
conditions.
In order to probe the mechanism of inhibition of
aggregation, we first examined the interaction of
clusterin with the native state of lysozyme by means
of size-exclusion chromatography and ELISA assays.
No species of increased mass (representing a
lysozyme/clusterin interaction) was detectable by
either assay; even in solutions containing equimolar
ratios of clusterin-to-lysozyme; i.e. at 80 times the
level at which clusterin was observed to inhibit fibril
formation (Figure 3). We then probed the interaction
of clusterin with the transient, partially unfolded
lysozyme species that has been identified as a
precursor to amyloid aggregation.28 To achieve this
objective, we monitored the rates of solvent
exchange of labile hydrogen in the protein by mass
spectrometry, under conditions where the exchangerates are fast compared to the local co-operative
unfolding process that generates the aggregation-
prone intermediate (i.e. EX1 conditions); the pre-
sence and nature of the latter can then be monitored
directly.9 Moreover, as well as characterizing the
intermediate, we have used this approach to show
that the inhibition of fibril formation by an antibody-
binding domain results from the stabilization of the
cooperative nature of the folded native state, which
in turn inhibits the formation of the transient
intermediate.10 We therefore compared the hydro-
gen exchange behavior of I56T lysozyme in the
absence and in the presence of clusterin (Figure 4(a)).
The results reveal that even at high clusterin-to-
lysozyme ratios (1:1.5), the rate of formation of the
intermediate and the number of protected amides is
not detectably altered by the presence of clusterin
(Figure 4(b)). Thus, even under these conditions,
I56T lysozyme is still able to populate the transient
intermediate, whose properties appear unchanged,
Figure 2. Inhibition of I59T
lysozyme fibril formation by clus-
terin. (a) Light-scattering results
from I59T aggregation in the ab-
sence of clusterin (black) and with a
molar ratio of 1:40 clusterin-to-
lysozyme (red). The light-scattering
intensity for clusterin alone is
shown in blue. Samples were incu-
bated with stirring at 60 °C and the
light-scattering was monitored at
500 nm. (b) TEManalysis of samples
taken at the end of the growth phase
observed in the light-scattering
assay. Clusterin alone under these
conditions showed species identical
with those seen in Figure 1(b). The
scale bar represents 500 nm. (c)
Thioflavin-T fluorescence measured
at the end of the growth phase ob-
served in the light-scattering assay
for buffer only (green) and I59T
alone (black). (d) SDS-PAGEanalysis
of samples at the end of the growth
phase observed in the light-scatter-
ing assay after being passed through
0.22 μm pore size filters. No soluble
protein remained in the I59T sample
in the absence of clusterin (lane 1);
however, the majority of lysozyme
remained in the soluble form in the
sample containing clusterin (lane 2).
Molecular mass markers are shown
in lane M, and an equal volume of a
soluble I59T lysozyme solution
(7 μM) is shown in lane S.
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fibril formation does not result from its influence on
this intermediate state but on a step that is
subsequent to its formation in the aggregation
pathway.
As it has been shown that clusterin does not
interact detectably with monomeric lysozyme or
the monomeric transient intermediate, but is able
to inhibit fibril formation when added at sub-
molar ratios at the beginning of the reaction, we
attempted to define the stage of the aggregation
reaction at which clusterin is most effective.
Addition of substoichiometric amounts of clus-
terin at the beginning of the reaction results in the
inhibition of fibril formation over the entire time-
course of the reaction that we analyzed. When,
however, the same amount of clusterin was added
mid-way through the elongation phase of lyso-
zyme fibril formation, the degree to which
clusterin inhibits aggregation was much less
than that resulting from the earlier addition
(Figure 5). It can be concluded, therefore, that
the species recognized by clusterin must be
populated in the lag phase of fibril formation
and that, once fibril elongation and growth has
begun, the effect of clusterin is substantially
compromised.The inhibitory effect of clusterin must therefore
occur subsequent to the formation of the transient
intermediate but before the elongation phase. In
order to narrow down the species involved still
further, we studied the non-native variant of human
lysozyme, I59T, which, under the fibril-forming
conditions used for this variant, possesses a highly
reproducible lag phase of about 2.8 h, to probe for
the presence of clusterin/lysozyme complexes. We
attempted this task first by using a dot blot analysis,
in which samples of different time-points during the
lag phase of lysozyme were incubated with clus-
terin. However, no complex was detected reprodu-
cibly at the sensitivity we were able to achieve in this
assay. In order to gain additional sensitivity as well
as to search for the complex in situ, we instead
incubated a 1:8 molar ratio of clusterin-to-lysozyme
under fibril-forming conditions, and removed ali-
quots at different time-points for analysis in micro-
titer plate wells containing an immobilized
monoclonal anti-clusterin antibody. After incuba-
tion, the wells were washed and probed with a
lysozyme-specific antibody; a positive result indi-
cated the presence of a complex. Using this
approach, we were able to detect a complex demon-
strating that clusterin does indeed interact with one
or more types of species populated during the fibril
Figure 3. Analysis of interactions between clusterin and native I56T lysozyme. (a) Analysis by size-exclusion
chromatography of clusterin alone, I56T alone, and a mixture of I56T and clusterin (at a 1:1 molar ratio). The result
obtained for the mixture of clusterin and I56T (experimental) does not differ significantly from the theoretical result
obtained by summing the traces for lysozyme alone and clusterin alone (i.e. assuming that there is no interaction between
clusterin and I56T lysozyme). The dotted red line represents the centre of the buffer peak in all spectra. (b) Interactions
between lysozyme and clusterin determined by ELISA. The graph displays the levels of clusterin bound to immobilized
IgG (positive control) and I56T and wild-type lysozymes. All experiments were performed in triplicate.
161Clusterin Inhibits Lysozyme Amyloid Formationlag phase (Figure 6). Analysis of the time-course of
clusterin binding indicates that a complex with
lysozyme is detected relatively late in the aggrega-
tion process. Indeed, binding appears at a time-point that, in the absence of clusterin, would be at
the end of the elongation phase (4.8 h) (Figure 6). In
the presence of clusterin, no significant light-
scattering is observed at this time, or at time-points
Figure 4. Effect of clusterin on
the transient intermediate of lyso-
zyme. (a) Time-points of hydrogen
exchange reactions as monitored by
mass spectrometry. In the presence
and in the absence of a 1:1.5 molar
ratio of clusterin-to-lysozyme, a
higher mass species dominates initi-
ally (after 10 s of exchange) (14,743.2
(±1.1) Da). As the time of exchange
increased, the intensity of the lower
mass species (14,704.2( ±3.7) Da)
increases and by 300 s is the sole
observable peak. The mass of deut-
erated I56T lysozyme is 14943.6 Da.
(b) The population of intermediate
is plotted versus time to determine
the rate of formation of the transient
intermediate. The half-times (τ1/2)
for I56T lysozyme in the absence
(black) and presence (red) of clus-
terin are 18.2(±2.4) sec and 21.2
(±2.2) s, respectively.
162 Clusterin Inhibits Lysozyme Amyloid Formationthat are twice as long. To ensure this signal is due to
the presence of a complex and not due to binding of
lysozyme aggregates to the microtiter plate wells,
aliquots taken at different time-points from the
samples containing lysozyme alone were investi-
gated. It is clear from these experiments that there is
no detectable non-specific binding of lysozyme
aggregates in this assay (Figure 6(c)). It should be
noted that the complex represents a very small
fraction of the overall reaction mixture; when the
flow-through was examined by SDS-PAGE, the
amount of soluble lysozyme still present in the
reaction mixture was greater than 95% (Figure 6(b)).
These findings therefore confirm that clusterinFigure 5. Effectiveness of the addition of clusterin at
different time-points during the light-scattering assay.
Light-scattering results of I59T lysozyme aggregation in
the absence of clusterin (black), and following addition of
clusterin to the I59T reaction in sub-stoichiometric
quantities (1:40) at time zero (red) and at t=2.9 h (green).
The time-dependence of the light-scattering for clusterin
alone is shown in blue.recognizes and binds to a species along the
lysozyme fibril-forming pathway, which with con-
tinued incubation under fibril-forming conditions,
forms detectable complexes. Moreover, the fact that
interactions with a very small fraction of the total
soluble lysozyme present suppresses the aggrega-
tion process suggests that this species is a key
intermediate on the route to fibril formation, and
that in the early stages of inhibition, clusterin has the
ability to reduce the population of this species
formed from reaching the threshold that leads to
fibril formation.Discussion
Clusterin has a remarkable ability to inhibit lyso-
zyme fibril formation even when present at a highly
sub-stoichiometric molar ratio. The very low levels
of clusterin that are sufficient to generate complete
inhibition for prolonged periods of time, together
with the lack of interaction between clusterin and
native lysozyme, suggests strongly that clusterin
exerts its effects by interacting with a species that
is not highly populated, yet crucial for the
aggregation process. Mass spectrometric analysis
reveals that this species is not the transient and
partially unfolded monomeric intermediate that
has been identified as the initial step in the
pathway of lysozyme amyloidogenesis.10,11 The
kinetics of this latter process show a clear lag
phase, followed by rapid exponential growth,
typical of amyloid formation in other systems.15
Under the conditions used in the present study,
complexes of clusterin with lysozyme species
formed in situ early in the lag phase were not
detectable, although in studies using much higher
concentrations of lysozyme, and indeed other
proteins, we have established that clusterin can
Figure 6. Detection of lyso-
zyme/clusterin complex under
fibril-forming conditions. (α) Light-
scattering of I59T in the absence of
clusterin (black) and I59T in the
presence of a clusterin-to-lysozyme
molar ratio of 1:8 (red). The time-
points analyzed for the presence of
complex are indicated. (b) SDS-
PAGE analysis of samples passed
through a 0.22 μm pore size filter.
Samples include molecular mass
markers (lane M), soluble lyso-
zyme (7 μM) (lane 1), lysozyme/
clusterin samples at 4.8 h (lane 2),
7.2 h (lane 3), 10 h (endpoint) of
I59T lysozyme alone (lane 4), 10 h
(endpoint) of I59T with clusterin
(lane 5). (c) Detection of the clus-
terin/lysozyme complex moni-
tored at 495 nm after probing
with anti-lysozyme antibodies. The
blank contained no sample, the
positive control had lysozyme ad-
sorbed to thewells, and the negative
control incubated lysozyme in wells
adsorbed to the anti-clusterin anti-
body. The red dotted line represents
the detected absorbance due to non-
specific binding based on the nega-
tive control.
163Clusterin Inhibits Lysozyme Amyloid Formationbind to preformed oligomeric species. The present
results reveal, however, that the dominant species
binding to clusterin accumulates to detectable levels
later in the aggregation process. These species are,
even at this stage of the reaction, present at very low
levels, enabling highly sub-stoichiometric amounts
of clusterin to inhibit aggregation effectively com-
pletely for lengths of time over which the lysozyme
variant in the absence of clusterin, converts into
amyloid fibrils. The lack of a stable complex early in
the aggregation process is likely to be due, in part, to
the lack of sensitivity in the detection methods. It is
interesting, however, that we do not detect a com-
plex until relatively late in the inhibition reaction,
which may suggest that the interaction between
clusterin and lysozyme in the early stages of aggre-
gation may be transient in nature. In this case, the
complex detected when lysozyme is in the presence
of clusterin could arise from the further association
of such species.
The oligomeric species populated during the phase
of protein aggregation before the formation of fibrils
are of particular interest, both because of their
evident role in nucleating fibril growth, and because
the relatively small oligomers involved in misfolded
aggregates with high surface-to-volume ratios
appear to be highly toxic.20 These species, are,
however, intrinsically heterogeneous and the aggre-gates observed in the present studymay represent, at
least in part, the continuous association of small
oligomers.20 Indeed, it appears extremely likely that
clusterin prevents lysozyme aggregation by inter-
acting with the variety of oligomeric species devel-
oping along the fibril-forming pathway. It is
interesting to note, however, that recent studies
have implicated oligomers of the size range observed
in the present work as the most effective species
inducing fibril formation, probably by nucleation
of β-sheet formation within the larger oligomeric
species.29 From the present results and other
studies, this evidence suggests that clusterin is
likely to interact preferentially with small soluble
oligomers.30,31
The inhibitory effect of clusterin is fully consistent
with a model for fibril formation by human
lysozyme, in which protein molecules overwhel-
mingly populate the native state, but structural
fluctuations in the amyloidogenic variants can
readily lead to a high enough population of partially
unfolded monomeric precursors to initiate the
aggregation process (Figure 7).32 The recent demon-
stration that inhibition of fibril formation can occur
as a result of the binding of antibody fragments,
preventing the formation of this transient mono-
meric species, supports the importance of this
species as a precursor to oligomer formation.10 It is
Figure 7. Proposed pathway for
lysozyme fibril formation and it's
inhibition by clusterin. Lysozyme
exists primarily in its native state
under physiological conditions. In
the amyloidogenic variants, the
decreased native state stability and
reduction in cooperativity results in
the transient formation of an inter-
mediate at concentrations high
enough to be detected using hydro-
gen exchange monitored by mass
spectrometry.32 The formation of
intermolecular interactions between
such intermediates can generate
oligomeric species that are subse-
quently able to nucleate fibril
growth. The ways which clusterin
could inhibit such events are indi-
cated in red.
164 Clusterin Inhibits Lysozyme Amyloid Formationtherefore likely that the oligomeric species, which
are likely to be highly heterogeneous, may be
recognized in vivo by clusterin before the accumula-
tion of extracellular amyloid deposits and the onset
of amyloidosis.
The mechanism of inhibition of lysozyme amy-
loid formation by clusterin that has been deduced
from the present study, along with the ubiquitous
presence of relatively high levels of clusterin in
different tissues, strongly supports the concept that
clusterin has an important, and general, role in
avoiding protein aggregation. Our results show
that clusterin is most effective at inhibiting fibril
formation when present early in the lag phase of the
aggregation process, an observation consistent with
the findings from studies of the inhibition of
apolipoprotein C-II fibril formation by clusterin
and by another molecular chaperone, α-crystallin
that is classified as a small heat-shock protein.30,31,33
Protein misfolding is not confined to a small
number of proteins, but is an inherent consequence
of the stochastic nature of the process of proteinfolding and refolding.1,16 Moreover, proteins have
an innate tendency to aggregate under some
conditions. It appears likely, therefore, that clusterin
has an important role in suppressing such effects
under normal physiological conditions.
The ability of clusterin to accumulate oligomeric
species to form relatively stable complexes suggests
that extracellular deposition of amyloid fibrils result,
for example, in situations when larger than normal
populations of misfolded proteins and oligomers
appear. Such situations can be the result of muta-
tions, such as in lysozyme amyloidosis, or other
factors, such as an increase in protein levels e.g. of
β2-microglobulin in dialysis-related amyloidosis,34
or a decrease in the efficacy of the various protective
mechanisms against aggregation that can occur in
old age.35 Moreover, the key role played by clusterin
in our mechanisms of defense against amyloid
formation suggests that enhancement of its levels
in tissue, or of its ability to sequester or induce
clearance of aggregates, could be a potential
therapeutic strategy.
165Clusterin Inhibits Lysozyme Amyloid FormationMaterials and Methods
The I56T and I59T human lysozyme variants were
expressed and purified as described.36,37 Human clus-
terin was purified from serum by immunoaffinity chroma-
tography as described.38 For secondary purification, the
eluate was dialyzed against 20 mM Tris–HCl (pH 8.0) and
loaded onto a Q-Sepharose column. Bound proteins were
eluted using a 0 M–0.7 M NaCl gradient in the same buffer
and clusterin-containing fractions were pooled and con-
centrated. For all proteins, stock solutions of lyophilized
material were made in Milli-Q water. Stock solutions were
passed through 0.22 μm pore size filters and concentrations
were determined by UV-visible spectroscopy as described;7
dilutions into appropriate buffersweremade for each assay.
Monoclonal anti-clusterin antibodies, G7 and 41D, were
generated as described,39 and polyclonal anti-human
lysozyme antibodies were prepared in rabbits by Washing-
ton Biotechnology Inc. (Simpsonville, MD, USA).Aggregation monitored by right-angle light-scattering
Aggregation studies were performed with I56T human
lysozyme (6.8 μM, 0.1 M sodium citrate buffer pH 5.0),
incubated with stirring at 48 °C in a Cary Eclipse
spectrofluorimeter (Varian Ltd., Oxford UK), or with a
non-natural lysozyme variant, I59T (6.8 μM, 0.1 M sodium
citrate buffer pH 5.0) incubated at 60 °C with stirring.
Light-scattering was monitored at 500 nmwith slit-widths
of 5 nm. Inhibition of fibril formation by clusterin was
monitored in the same fashion using a range of clusterin-
to-lysozyme molar ratios (1:80, 1:40, 1:8 or 1:4). These
ratios were calculated from the monomeric molecular
mass of the lysozyme variants (14,680.6 Da for both) and
from amass of 61 kDa for clusterin based on the average of
two reported glycoforms.21Thioflavin-T binding
A stock solution of thioflavin-T (Thio-T) (2.5 mM) was
prepared in 10 mM sodium phosphate buffer (pH 7.0)
containing 150 mM NaCl. Fresh stock solutions were
prepared daily and passed through 0.22 μm pore size
filters. Samples were prepared with 100 μl endpoint
aliquots in 0.1 M sodium citrate buffer (pH 5.0) containing
62.5 μM Thio-T. Thio-T binding was measured in a Cary
Eclipse spectrofluorimeter with an excitation wavelength
of 440 nm (slit-width 5 nm) and an emission scan from 450–
600 nm (slit-width 5 nm). All experiments were performed
in triplicate unless stated otherwise.Transmission electron microscopy (TEM)
Samples were applied to Formvar-coated nickel grids,
stained with 2% (w/v) uranyl acetate solution and viewed
in a Philips CEM100 transmission electron microscope
operating at 80 kV as described.10SDS-PAGE analysis
Samples were passed through a 0.22 μmpore size PVDF
filter. The filtrates were analyzed by SDS-PAGE using 4%–
12% Bis-Tris NuPAGE gels (Invitrogen UK) in Mes buffer
under non-reducing conditions. Gels were stained using
Coomassie brilliant blue.Hydrogen exchange monitored by electrospray
ionization mass spectrometry
I56T human lysozyme was deuterated at exchangeable
sites by unfolding in deuterated guanidinium hydro-
chloride.9 The proteins were refolded via dilution in
2H2O and concentrated in a Vivaspin 20 concentrator
(Sartorius Ltd., Epsom UK) with a molecular mass cut-
off of 5 kDa. This cycle of dilution and concentration
was repeated until no guanidinium ion contamination
was observable by mass spectrometry. The final stock
solutions of protein were 200 μM in 2H2O. Deuterated
I56T (200 μM in 2H2O) was added to lyophilized
clusterin to give a 1:1.5 clusterin-to-lysozyme molar
ratio. Samples were prepared for hydrogen/deuterium
(H/D) exchange by manual mixing as described.14
Spectra were acquired over a mass/charge range of
500 to 5000 Da on an LCT MS instrument (Waters Ltd.,
Elstree, UK) equipped with a nanoflow Z-spray source
and calibrated with CsI (15 μM). Data were analyzed
using MassLynx 3.4 (Waters Ltd.) with molecular masses
calculated from the centroid values of at least three
charge states. The mass spectra shown represent the
convolution of three charged species with minimal
smoothing and converted to a mass scale.
Size-exclusion chromatography to detect native
interactions
I56T lysozyme (7 μM, 0.1 M sodium citrate buffer, pH
5.0) and clusterin (8.7 μM, 0.1 M sodium citrate buffer, pH
5.0) were incubated at 37 °C for 30 min both alone and
together. Following this procedure, a 50 μl sample was
injected onto a BioSep-SEC-S 4000 column (Phenomenex,
Sydney, Australia) using a Shimadzu HPLC System
(Shimadzu Scientific Instruments, Sydney, Australia)
with autosampler (model SIL-10Ai) and diode array
detector (model SPD-M10AVP). The column was run at
a flow-rate of 0.5 ml/min. The UV traces shown are
representative of three separate runs.
ELISA assay to detect native interactions
I56T lysozyme (100 μg/ml, 0.1 M sodium citrate buffer,
pH 5.0) was adsorbed on to the wells of a 96-well
microtiter plate for 1 h at 37 °C. The wells were blocked
(1 h, 37 °C) with HDC (10 mM phosphate, 150 mM NaCl,
1% (w/v) heat-denatured casein, 0.04% (w/v) thymol, pH
7.4). Aliquots (100 μl) of purified clusterin (10 μg/ml in
HDC) were added to these wells, incubated for 1 h at
37 °C, and then washed repeatedly with PBS to remove
any unbound clusterin. Bound clusterin was detected
using a mixture of purified G7 and 41D mouse anti-
human-clusterin monoclonal antibodies (5 μg/ml of each),
followed by treatment with an anti-mouse IgG secondary
antibody conjugated to alkaline phosphatase (Wester-
nBreeze Chromogenic Immunodetection System, Invitro-
gen UK). Detection was performed spectrometrically at
405 nm, after addition of p-nitrophenol phosphate.
ELISA pull-down assay to detect lysozyme/clusterin
complex
Purified G7 anti-clusterin antibody (5 μg/ml in PBS) or
I59T human lysozyme (0.1 mg/ml) was adsorbed on to
the wells of a 96-well microtiter plate (1 h, 37 °C),
followed by washing six times with PBS. The wells were
166 Clusterin Inhibits Lysozyme Amyloid Formationblocked using the Westernbreeze (Invitrogen UK) block-
ing reagent (casein and detergent) (1 h, 37 °C). Time-
points from a lysozyme aggregation reaction in the
presence of a 1:8 molar ratio of clusterin to lysozyme
were incubated in the wells (1 h, 37 °C), biotinylated
clusterin was incubated as a positive control for clusterin
binding, and lysozyme (0.1 mg/ml) was incubated as a
positive control for lysozyme detection. The wells were
washed six times with PBS followed by incubation with a
1:1000 dilution of anti-lysozyme antibody or a 1:2000
dilution of streptavidin-alkaline phosphatase (for bioti-
nylated clusterin). The wells were again washed with PBS
(six times) and incubated for 1 h at 37 °C with an anti-
rabbit IgG secondary antibody conjugated to alkaline
phosphatase. The wells were washed six times with Tris-
buffered saline. Detection was performed with the ELISA
amplification kit (Invitrogen UK), following the manufac-
turer's instructions.Acknowledgements
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